US Recall News

United States Recall News Alerts for Recalled Drugs, Food, Products, & Vehicles

MENUMENU
  • Home
  • About
    • Advertise
  • Full Recall News Archive
    • Top Story

      J&J Settles Talc Mesothelioma Settlement

      By Sandra Dalton, Staff Writer On January 6, 2020, Superior Court Judge Stephen Kaus announced that Johnson & Johnsons (J&J) had agreed to … [Read More...]

      Daiso Issues Allergy Alert for Prepackaged Snacks

      Summary Company Announcement Date: February 03, 2023 FDA Publish Date: … [Read More...]

    • More Safety Articles
    • Federal Preemption of State Product Liability Law
  • Drug Recalls
    • Abilify
    • Benicar
    • Fluoroquinolones
    • Invokana
    • Lipitor
    • Nuplazid
    • Opioids
    • OxyContin
    • Pradaxa
    • Proton Pump Inhibitors (PPIs)
    • Risperdal
    • SSRI
    • Symptoms & Side Effects
    • Taxotere
    • Testosterone
    • Uloric
    • Valsartan
    • Xarelto
    • Zofran
  • Medical Devices
    • 3M Earplug
    • 3T Heater-Cooler System
    • Bair Hugger
    • Bipolar Hip System
    • Essure
    • Hip Replacements
    • Implanon
    • IVC Filters
    • Hernia Mesh
    • Power Morcellators
    • Shoulder Implants
    • Transvaginal Mesh
  • Food Recalls
    • FDA Press Releases
    • USDA Press Releases
  • Auto Recalls
    • Air Bags
    • Ignitions
    • NHTSA Press Releases
    • Off-Road Utility Vehicles
    • Snowmobiles
    • Tires
  • Other Products
    • Asbestos
    • Baby Products
    • Pet Products
    • Roundup
    • Talcum Powder
    • Toy Recalls
You are here: Home / Food Recalls / FDA Press Releases / Astrazeneca Initiates Voluntary Nationwide Recall of One Lot of Brilinta 90 mg Professional Sample Bottles Due to Report of Another Medicine in One Bottle From That Lot

Astrazeneca Initiates Voluntary Nationwide Recall of One Lot of Brilinta 90 mg Professional Sample Bottles Due to Report of Another Medicine in One Bottle From That Lot

May 26, 2017 By The FDA Leave a Comment

Voluntary recall limited to Lot # JB5047 of BRILINTA® (ticagrelor) 90 mg tablets, 8-count Professional (Physician) Sample Bottles

Other forms or dosage strengths of BRILINTA, including medicine obtained via US retail or mail order pharmacies, are not affected by this voluntary recall

AstraZeneca today announced that the Company is notifying physicians and consumers that it is voluntarily recalling one lot of professional (physician) sample bottles containing eight tablets of BRILINTA® (ticagrelor) 90mg tablets as a precautionary measure. This voluntary recall follows a report that a professional sample bottle containing eight tablets of BRILINTA 90mg also contained another medicine called ZURAMPIC® (lesinurad) 200 mg tablets which is also manufactured by AstraZeneca.

This precautionary measure is limited to one lot (BRILINTA lot #JB5047) of professional sample bottles containing eight tablets of BRILINTA 90 mg distributed to physicians in the US between March and April of 2017. Other forms and dosage strengths of BRILINTA, including medicine obtained via US retail or mail order pharmacies, are not affected by this voluntary recall. This recall does not affect ZURAMPIC.

Unintentional dosing with ZURAMPIC has the potential to lead to adverse renal effects including acute renal failure which is more common when ZURAMPIC is given alone as it should be used in combination with a xanthine oxidase inhibitor. BRILINTA has a warning in its prescribing information regarding discontinuation of the medicine. Missed doses of BRILINTA increases the risk of heart attack and stroke. People who are treated with a stent and miss doses of BRILINTA have a higher risk of getting a blood clot in the stent, having a heart attack, or death. Patients should not stop taking BRILINTA without talking to their prescribing doctor. To date, AstraZeneca has not received any reports of adverse events related to this recall.

BRILINTA is indicated to reduce the rate of CV death, heart attack and stroke in patients with acute coronary syndrome (ACS) or a history of heart attack. BRILINTA also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS. ZURAMPIC is a prescription medicine used together with a xanthine oxidase inhibitor such as allopurinol or Uloric in adults with gout who still have a high uric acid level.

BRILINTA 90 mg tablets are supplied as a round, biconvex, yellow, film-coated tablet, and imprinted with 90 above a T on one side of the pill. ZURAMPIC tablets 200 mg are blue in color and elliptical/oval in shape. They are imprinted with LES200 on one side of the pill.

AstraZeneca is notifying physicians by recall letter and is arranging for return of all recalled products. Consumers that have medicine which is being recalled should contact their physician.

Consumers with questions regarding this recall can contact AstraZeneca Information Center at 1-800-236-9933 between the hours of 8 a.m. and 6 p.m. (Eastern Time) Monday to Friday, excluding holidays. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this medicine.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Patient safety is a top priority for AstraZeneca and we are working closely on this recall with the knowledge of the U.S. Food and Drug Administration in taking the appropriate course of action.

###

Share this:

  • Facebook
  • Twitter
  • LinkedIn
  • Email
  • Print

Related

Filed Under: FDA Press Releases, Uloric

About The FDA

The Food and Drug Administration (FDA) is an agency within the U.S. Department of Health and Human Services. It consists of the Office of the Commissioner and four directorates overseeing the core functions of the agency: Medical Products and Tobacco, Foods and Veterinary Medicine, Global Regulatory Operations and Policy, and Operations.

Leave a Reply Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Facebook
Thomas Roney LLC
Economic Consulting

J&J Settles Talc Mesothelioma Settlement

January 15, 2020 By Advice Media

Daiso Issues Allergy Alert for Prepackaged Snacks

February 3, 2023 By The FDA

Daiso Issues Alergy Alert for Prepackaged Snacks

February 3, 2023 By The FDA

Fresh Ideation Food Group LLC Recalls Sandwiches and Other Products Because of Possible Health Risk

February 3, 2023 By The FDA

Hero Highlight

J&J Settles Talc Mesothelioma Settlement

January 15, 2020 By Advice Media

Children’s Robes Recalled Due to Violation of Federal Flammability Standard and Burn Hazard; Imported by Betusline Official Apparel; Sold Exclusively on Amazon.com

February 1, 2023 By The CPSC

Children’s Robes Recalled Due to Violation of Federal Flammability Standards and Burn Hazard; Imported by BTPEIHTD; Sold Exclusively at Amazon.com

February 1, 2023 By The CPSC

Children’s Robes Recalled Due to Violation of Federal Flammability Standards and Burn Hazard; Imported by ChildLikeMe; Sold Exclusively at Amazon.com

February 1, 2023 By The CPSC

Children’s Robes Recalled Due to Violation of Federal Flammability Standards and Burn Hazard; Imported by SGMWVB Brand; Sold Exclusively on Amazon.com

February 1, 2023 By The CPSC

Shop Me Ca Recalls “Diep Bao Cream” Because of Possible Health Risk

February 1, 2023 By The FDA

J&J Settles Talc Mesothelioma Settlement

January 15, 2020 By Advice Media

Children’s Robes Recalled Due to Violation of Federal Flammability Standards and Burn Hazard; Imported by SGMWVB Brand; Sold Exclusively on Amazon.com

February 1, 2023 By The CPSC

Shop Me Ca Recalls “Diep Bao Cream” Because of Possible Health Risk

February 1, 2023 By The FDA

B&G Foods Issues Voluntary Allergy Alert for Undeclared Peanut in Three Cases of Back to Nature® Fudge Mint Cookies

January 31, 2023 By The FDA

Recall News in Your Inbox

Enter your email address to receive automated recall news updates.

Recent Comments

  • Roger McGowan on ABH NATURE’S PRODUCTS, INC, ABH PHARMA, INC., and STOCKNUTRA.COM, INC. Issues Nationwide Recall of All Lots of Dietary Supplement Products
  • Kathryn Moore on FDA Wants Cancer Warning on Breast Implants
  • BRAD on Huge ATV Recall by Polaris – Sportsman and Scrambler
  • Crystal Anderson on Allergan Voluntarily Recalls BIOCELL® Textured Breast Implants and Tissue Expanders
  • Outsourcing Training on The Modern Marketing of Pain
  • SANDRA Collett on Processed Food Preservative Linked to Autism?
  • Eric Karsh on Health Risks of Roundup Go Well Beyond Cancer

Recent Posts

  • Daiso Issues Allergy Alert for Prepackaged Snacks
  • Daiso Issues Alergy Alert for Prepackaged Snacks
  • Fresh Ideation Food Group LLC Recalls Sandwiches and Other Products Because of Possible Health Risk
  • Global Pharma Healthcare Issues Voluntary Nationwide Recall of Artificial Tears Lubricant Eye Drops Due to Possible Contamination
  • Paper Cape Recalls Children’s Pajamas Due to Violation of Federal Flammability Standards and Burn Hazard
  • Children’s Robes Recalled Due to Violation of Federal Flammability Standard and Burn Hazard; Imported by Betusline Official Apparel; Sold Exclusively on Amazon.com
  • Children’s Robes Recalled Due to Violation of Federal Flammability Standards and Burn Hazard; Imported by BTPEIHTD; Sold Exclusively at Amazon.com
  • Children’s Robes Recalled Due to Violation of Federal Flammability Standards and Burn Hazard; Imported by ChildLikeMe; Sold Exclusively at Amazon.com
  • Children’s Robes Recalled Due to Violation of Federal Flammability Standards and Burn Hazard; Imported by SGMWVB Brand; Sold Exclusively on Amazon.com
-- See More Recall News

Disclaimer: The information contained in these topics is not intended nor implied to be a substitute for professional medical or legal advice, it is provided for educational purposes only. Always seek the advice of your physician or other qualified healthcare provider about any questions you may have regarding a medical condition. Nothing contained in these topics is intended to be used for medical diagnosis or treatment.


ATTORNEY ADVERTISING. The information provided on this website is not legal advice. No attorney-client relationship is formed by the use of this site. It is not stated or implied that a lawyer is certified as a specialist in any particular field of law. No results are guaranteed, and prior results do not guarantee a similar outcome. This site is informational, only, not dispositive; it is up to you to decide whether a particular lawyer is right for you. Use of this site is subject to your agreement to these.


Copyright © 2023 Altrumedia · Terms of Service · Log in